Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Crysvita (burosumab-twza) is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older, and for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Burosumab significantly increased serum phosphorus levels in patients with X-linked hypophosphatemia (XLH), with an increase of 0.52 mg/dL (95% CI 0.24-0.80 mg/dL) in randomized controlled trials and 0.78 mg/dL (95% CI 0.61-0.96 mg/dL) in the overall meta-analysis.
• In XLH patients, Burosumab significantly increased TmP/GFR by 0.86 mg/dL (95% CI 0.60-1.12 mg/dL) and 1,25-dihydroxyvitamin D levels by 13.23 pg/mL (95% CI 4.82-21.64 pg/mL), demonstrating effectiveness in improving phosphate metabolism.
• Burosumab is highlighted as a promising nonsurgical therapy for patients with tumor-induced osteomalacia (TIO), especially in cases of persistent, recurrent, or inoperable TIO, with evidence of potential effectiveness in a small cohort of patients.
• In RCTs, the safety profile of burosumab in patients with X-linked hypophosphatemia (XLH) was not significantly different from the control group.
• In single-arm trials for XLH, there was a high incidence of treatment-emergent adverse events (TEAEs), with most being mild to moderate in severity and a low rate of serious TEAEs.
• No specific safety concerns or adverse effects were detailed for tumor-induced osteomalacia (TIO) patients treated with burosumab in the provided studies.